3 Small-Cap Stocks Walking a Fine Line

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here are three small-cap stocks to swipe left on and some alternatives you should look into instead.

Spectrum Brands (SPB)

Market Cap: $2.04 billion

A leader in multiple consumer product categories, Spectrum Brands (NYSE:SPB) is a diversified company with a portfolio of trusted brands spanning home appliances, garden care, personal care, and pet care.

Why Should You Dump SPB?

1. Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
2. Projected sales growth of 1.6% for the next 12 months suggests sluggish demand
3. Low returns on capital reflect management’s struggle to allocate funds effectively

At $88.69 per share, Spectrum Brands trades at 18.6x forward P/E. Check out our free in-depth research report to learn more about why SPB doesn’t pass our bar.

Caleres (CAL)

Market Cap: $398 million

The owner of Dr. Scholl's, Caleres (NYSE:CAL) is a footwear company offering a range of styles.

Why Is CAL Risky?

1. Lackluster 3.6% annual revenue growth over the last five years indicates the company is losing ground to competitors
2. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
3. High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens

Caleres is trading at $11.84 per share, or 6.9x forward P/E. Dive into our free research report to see why there are better opportunities than CAL.

Novavax (NVAX)

Market Cap: $1.35 billion

Pioneering a nanoparticle technology that mimics the molecular structure of disease pathogens, Novavax (NASDAQ:NVAX) develops and commercializes protein-based vaccines for infectious diseases, with a primary focus on its COVID-19 vaccine and combination respiratory vaccine candidates.

Why Do We Think NVAX Will Underperform?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 22.6% annually over the last two years
2. Projected sales decline of 50.7% over the next 12 months indicates demand will continue deteriorating
3. Cash burn makes us question whether it can achieve sustainable long-term growth

Novavax’s stock price of $8.19 implies a valuation ratio of 4.6x forward price-to-sales. Read our free research report to see why you should think twice about including NVAX in your portfolio.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.